CD-15 Immunohistochemistry at Test Zone Diagnostic Center

CD-15 Immunohistochemistry at Test Zone Diagnostic Center

CD-15 Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized, state-of-the-art pathology investigation used to detect the expression of the CD15 antigen in tissue specimens. CD15, also known as Lewis X or 3-fucosyl-N-acetyllactosamine, is a carbohydrate adhesion molecule expressed on the cell membranes of various normal and neoplastic cells. This diagnostic test is primarily performed on formalin-fixed, paraffin-embedded (FFPE) tissue biopsies or surgical resection specimens. By utilizing advanced monoclonal antibodies, our pathology laboratory in Lahore, Pakistan, can precisely identify the presence, distribution, and intensity of CD15 expression, providing critical diagnostic insights for oncologists, hematologists, and general physicians.

The clinical importance of CD-15 Immunohistochemistry lies in its exceptional diagnostic value for characterizing hematological malignancies and solid tumors. It is widely recognized as a cornerstone marker in the diagnostic panel for classical Hodgkin lymphoma (cHL), where it typically highlights the pathognomonic Reed-Sternberg cells. Additionally, CD15 plays a vital role in differentiating epithelial malignancies, such as adenocarcinoma, from pleural mesothelioma, and in classifying various subtypes of acute myeloid leukemia (AML). At Test Zone Diagnostic Center, we utilize advanced automated staining platforms and high-affinity antibodies to ensure maximum sensitivity and specificity, minimizing background staining and delivering highly reproducible results that guide critical therapeutic decisions.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-15 Immunohistochemistry is a laboratory-based analysis performed on tissue samples that have already been extracted, there is no direct physical preparation required from the patient on the day of the test. However, patients and referring physicians should keep the following preparation guidelines in mind:

• Submission of Tissue Blocks: Patients must provide the original Formalin-Fixed Paraffin-Embedded (FFPE) tissue block (often referred to as the ‘biopsy block’) along with the corresponding hematoxylin and eosin (H&E) stained glass slides.
• Clinical History: It is essential to submit a complete clinical history, previous pathology reports, and relevant radiological findings to assist our consultant pathologists in their evaluation.
• Biopsy Site Details: Ensure that the anatomical site of the biopsy and the date of the procedure are clearly documented on the referral form.
• No Fasting Required: Since the test does not involve a direct blood draw or immediate physical intervention, fasting or dietary restrictions are not necessary.
• Medication Review: Patients do not need to discontinue any routine medications unless specifically instructed by their primary physician prior to the initial biopsy procedure.

During the Procedure

The laboratory phase of CD-15 Immunohistochemistry at Test Zone Diagnostic Center involves a series of highly controlled, automated steps executed by experienced histotechnologists and supervised by consultant pathologists:

• Sectioning: The submitted paraffin block is mounted on a microtome, and ultra-thin sections (approximately 3 to 4 microns thick) are cut and mounted on positively charged glass slides to prevent tissue detachment.
• Deparaffinization and Rehydration: The slides are heated and treated with xylene to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue.
• Antigen Retrieval: To expose the CD15 epitopes masked during formalin fixation, the slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions under controlled temperature and pressure.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary monoclonal anti-CD15 antibody. This antibody binds specifically to the CD15 carbohydrate antigen present on the cell surfaces.
• Detection and Visualization: A secondary antibody conjugated with an enzyme (such as horseradish peroxidase) is applied, followed by a chromogen substrate (usually diaminobenzidine or DAB). This chemical reaction produces a visible brown precipitate at the site of antigen-antibody binding.
• Counterstaining and Coverslipping: The slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, and sealed with a coverslip for microscopic examination.
• Pathological Evaluation: A consultant pathologist examines the stained slides under a high-resolution light microscope, assessing the staining pattern (membranous, cytoplasmic, or paranuclear globular) and comparing it with positive and negative tissue controls.

When is a CD-15 Immunohistochemistry Performed?

Suspected Hodgkin Lymphoma Diagnosis

Physicians request CD-15 Immunohistochemistry when a patient presents with clinical features suggestive of classical Hodgkin lymphoma, such as persistent, painless lymphadenopathy, fever, night sweats, and unexplained weight loss. The test is critical because classical Hodgkin lymphoma is characterized by the presence of multinucleated Reed-Sternberg cells, which typically express CD15 in a distinctive membranous and paranuclear globular (Golgi zone) pattern. Confirming CD15 positivity, in conjunction with CD30, helps pathologists confidently differentiate classical Hodgkin lymphoma from non-Hodgkin lymphomas and reactive follicular hyperplasia, ensuring the patient receives the correct chemotherapeutic regimen.

Differentiating Adenocarcinoma from Mesothelioma

In thoracic pathology, distinguishing between pulmonary adenocarcinoma and malignant pleural mesothelioma can be highly challenging due to overlapping histological features. Oncologists and pulmonologists frequently request CD-15 Immunohistochemistry as part of a diagnostic antibody panel to resolve this diagnostic dilemma. Adenocarcinomas of the lung and other epithelial organs typically show strong, diffuse CD15 positivity, whereas malignant mesotheliomas are almost universally negative for this marker. This differentiation is critical, as the treatment pathways, surgical options, and prognoses for these two malignancies differ significantly.

Evaluation of Acute Myeloid Leukemia (AML)

Hematopathologists utilize CD-15 Immunohistochemistry during the diagnostic workup of bone marrow biopsies from patients suspected of having acute myeloid leukemia. CD15 is a marker of myeloid differentiation and is expressed by mature granulocytes and their precursors. In AML, particularly the myelomonocytic (AML-M4) and monocytic (AML-M5) subtypes under the FAB classification, CD15 expression helps characterize the lineage of the blast cells. Identifying these immunophenotypic characteristics assists in precise disease subtyping, risk stratification, and the formulation of targeted induction chemotherapy protocols.

Investigating Unexplained Lymphadenopathy

When patients present with localized or generalized enlargement of the lymph nodes that does not resolve with standard antibiotic therapy, a lymph node biopsy is performed. If the initial H&E staining reveals atypical cellular infiltrates or large, abnormal cells, CD-15 Immunohistochemistry is ordered. This test helps determine whether the lymph node architecture is disrupted by a primary hematological malignancy, a metastatic carcinoma (which may express CD15), or a benign, reactive immunoblastic proliferation, thereby guiding the clinical team toward the appropriate specialty care.

Monitoring Disease Progression and Recurrence

For patients who have previously undergone treatment for Hodgkin lymphoma or CD15-positive carcinomas, a repeat biopsy may be performed if recurrent disease is suspected due to new symptoms or abnormal radiological findings. CD-15 Immunohistochemistry is performed on the recurrent tissue sample to confirm that the phenotypic profile of the tumor remains unchanged. This helps oncologists evaluate whether the disease has relapsed, transformed, or if a secondary malignancy has developed, allowing for timely adjustments in salvage therapy or stem cell transplantation planning.

What Does a CD-15 Immunohistochemistry Detect?

CD-15 Immunohistochemistry is designed to detect specific cellular and pathological features, including:

• The presence of the CD15 carbohydrate antigen on the surface of neoplastic cells.
• Distinctive paranuclear globular (Golgi-like) staining in Reed-Sternberg cells.
• Membranous staining patterns in classical Hodgkin lymphoma cells.
• CD15 expression in mature and immature neutrophilic granulocytes (serving as an internal positive control).
• Diffuse cytoplasmic and membranous staining in pulmonary adenocarcinoma cells.
• Absence of CD15 staining in malignant pleural mesothelioma cells.
• CD15 positivity in metastatic adenocarcinoma cells within lymph nodes.
• Lineage-specific CD15 expression in acute myeloid leukemia blasts (AML-M4 and AML-M5).
• Absence of CD15 expression in lymphoid leukemias (ALL) and most T-cell lymphomas.
• CD15 expression in renal cell carcinoma cells.
• CD15 positivity in gastric and colorectal adenocarcinoma specimens.
• The percentage of tumor cells showing positive immunoreactivity for CD15.
• The intensity of CD15 staining, graded as weak, moderate, or strong.
• The spatial distribution of CD15-positive cells within the tumor microenvironment.
• Absence of CD15 expression in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
• CD15 expression in certain transitional cell carcinomas of the urothelium.
• Presence of CD15 in pancreatic ductal adenocarcinoma tissue.
• CD15 expression in thyroid papillary carcinoma.
• Distinction between reactive histiocytic proliferations and malignant histiocytosis.
• Validation of tissue preservation and staining quality via positive internal granulocyte controls.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Lahore, Pakistan, we understand that waiting for pathology results can be an anxious time for patients and their families. Because immunohistochemistry involves complex, multi-step laboratory processing, antigen retrieval, antibody incubation, and detailed microscopic analysis by a consultant pathologist, the turnaround time for CD-15 Immunohistochemistry is typically 3 to 5 working days from the receipt of the tissue specimen. Once the diagnostic report is finalized and signed off by our consultant pathologist, patients receive an automated SMS notification. Reports can be easily accessed and downloaded online through the secure patient portal on the Test Zone Diagnostic Center official website, or collected in person from our main diagnostic facility in Lahore.

CD-15 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Reed-Sternberg Cells	Absent (Not present in normal tissue)	Positive (Membranous and paranuclear Golgi staining in Classical Hodgkin Lymphoma)
Granulocytes (Neutrophils)	Strong, diffuse cytoplasmic and membranous positivity	Loss of expression (rare, may indicate myeloid maturation arrest or staining artifact)
Mesothelial Cells	Negative	Positive (rare, suggests epithelial differentiation or metastatic adenocarcinoma)
Pulmonary Epithelium	Negative to weak focal staining	Strong, diffuse cytoplasmic/membranous positivity (suggests Pulmonary Adenocarcinoma)
Lymphocytes (Normal B and T cells)	Negative	Positive (abnormal, requires evaluation for specific lymphoma subtypes)
Myeloblasts (Bone Marrow)	Negative to weak focal expression	Moderate to strong diffuse positivity (indicates myeloid differentiation in AML)
L&H Cells (NLPHL)	Absent (Not present in normal tissue)	Typically Negative (helps differentiate NLPHL from Classical Hodgkin Lymphoma)
Colonic Mucosa	Negative to weak apical staining	Strong, diffuse positivity (suggests Colorectal Adenocarcinoma)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-15 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive expertise in histopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: We adhere to stringent internal and external quality control protocols to ensure the highest level of diagnostic accuracy.
• Professional Reporting: Our pathology reports are comprehensive, detailed, and structured to provide clear, actionable insights for clinical decision-making.
• Modern Diagnostic Approach: We utilize advanced automated staining systems and high-affinity antibodies to minimize human error and background staining.
• Comfortable Environment: Our diagnostic center in Lahore offers a clean, professional, and welcoming environment for sample submission and inquiry.
• Convenient Location: Located centrally in Lahore, Pakistan, our facility is easily accessible for patients from all parts of the city and surrounding areas.
• Commitment to Accurate Diagnosis: We are dedicated to delivering precise, evidence-based diagnostic results that form the foundation of successful patient treatment.